Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Technology, Consumer Services and Financials sectors led shares lower. At the close in NYSE, the...
Axcella Therapeutics (NASDAQ:AXLA) reported Q4 EPS of ($0.46), $0.02 worse than the analyst estimate of ($0.44). For earnings history and earnings-related data on Axcella...
New Zacks Feature: ASK ALEXA Now call out a stock name or ticker. Alexa will give you its latest Zacks Rank and price. Also hear daily additions to and deletions from the...
SPECIAL ALERT: We’ve just released this quarter’s Ultimate Four report which includes four stocks our team believes have the greatest upside potential over the...
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
|Average||9.667 (+465.32% Upside)|
|No. of Analysts||6|